Efficacy of infliximab in intestinal Behçet's disease: A Korean multicenter retrospective study

Jin Ha Lee, JaeHee Cheon, Seong Woo Jeon, Byong Duk Ye, Suk Kyun Yang, Young Ho Kim, Kang Moon Lee, Jong Pil Im, Joo Sung Kim, Chang Kyun Lee, Hyo Jong Kim, Eun Young Kim, Kyeong Ok Kim, Byung Ik Jang, Won Ho Kim

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment. Methods: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea. We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab. Response rates of infliximab at 2, 4, 30, and 54 weeks for each patient and factors predictive of sustained response were investigated. Adverse events were also identified. Results: The median duration of follow-up after initial infliximab infusion was of 29.5 months. The clinical response rates at 2, 4, 30, and 54 weeks were 75%, 64.3%, 50%, and 39.1%, respectively, with clinical remission rates of 32.1%, 28.6%, 46.2%, and 39.1%, respectively. After multivariate analysis, older age at diagnosis (≥40 yr), female sex, a longer disease duration (≥5 yr), concomitant immunomodulator use, and achievement of remission at week 4 were found to be predictive factors of sustained response. There was 1 serious infection but no malignancies or deaths in this study. Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD. Moreover, we found 5 predictive factors associated with sustained response, which might assist in optimal patient selection for infliximab treatment.

Original languageEnglish
Pages (from-to)1833-1838
Number of pages6
JournalInflammatory Bowel Diseases
Volume19
Issue number9
DOIs
Publication statusPublished - 2013 Aug 1

Fingerprint

Intestinal Diseases
Multicenter Studies
Retrospective Studies
Patient Selection
Therapeutics
Infliximab
Immunologic Factors
Korea
Inflammatory Bowel Diseases
Tertiary Care Centers
Medical Records
Multivariate Analysis
Demography
Infection

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Cite this

Lee, Jin Ha ; Cheon, JaeHee ; Jeon, Seong Woo ; Ye, Byong Duk ; Yang, Suk Kyun ; Kim, Young Ho ; Lee, Kang Moon ; Im, Jong Pil ; Kim, Joo Sung ; Lee, Chang Kyun ; Kim, Hyo Jong ; Kim, Eun Young ; Kim, Kyeong Ok ; Jang, Byung Ik ; Kim, Won Ho. / Efficacy of infliximab in intestinal Behçet's disease : A Korean multicenter retrospective study. In: Inflammatory Bowel Diseases. 2013 ; Vol. 19, No. 9. pp. 1833-1838.
@article{c9c3d34a57914fd79c0c4ce89cff4da7,
title = "Efficacy of infliximab in intestinal Beh{\cc}et's disease: A Korean multicenter retrospective study",
abstract = "Background: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Beh{\cc}et's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment. Methods: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea. We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab. Response rates of infliximab at 2, 4, 30, and 54 weeks for each patient and factors predictive of sustained response were investigated. Adverse events were also identified. Results: The median duration of follow-up after initial infliximab infusion was of 29.5 months. The clinical response rates at 2, 4, 30, and 54 weeks were 75{\%}, 64.3{\%}, 50{\%}, and 39.1{\%}, respectively, with clinical remission rates of 32.1{\%}, 28.6{\%}, 46.2{\%}, and 39.1{\%}, respectively. After multivariate analysis, older age at diagnosis (≥40 yr), female sex, a longer disease duration (≥5 yr), concomitant immunomodulator use, and achievement of remission at week 4 were found to be predictive factors of sustained response. There was 1 serious infection but no malignancies or deaths in this study. Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD. Moreover, we found 5 predictive factors associated with sustained response, which might assist in optimal patient selection for infliximab treatment.",
author = "Lee, {Jin Ha} and JaeHee Cheon and Jeon, {Seong Woo} and Ye, {Byong Duk} and Yang, {Suk Kyun} and Kim, {Young Ho} and Lee, {Kang Moon} and Im, {Jong Pil} and Kim, {Joo Sung} and Lee, {Chang Kyun} and Kim, {Hyo Jong} and Kim, {Eun Young} and Kim, {Kyeong Ok} and Jang, {Byung Ik} and Kim, {Won Ho}",
year = "2013",
month = "8",
day = "1",
doi = "10.1097/MIB.0b013e31828f19c9",
language = "English",
volume = "19",
pages = "1833--1838",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

Lee, JH, Cheon, J, Jeon, SW, Ye, BD, Yang, SK, Kim, YH, Lee, KM, Im, JP, Kim, JS, Lee, CK, Kim, HJ, Kim, EY, Kim, KO, Jang, BI & Kim, WH 2013, 'Efficacy of infliximab in intestinal Behçet's disease: A Korean multicenter retrospective study', Inflammatory Bowel Diseases, vol. 19, no. 9, pp. 1833-1838. https://doi.org/10.1097/MIB.0b013e31828f19c9

Efficacy of infliximab in intestinal Behçet's disease : A Korean multicenter retrospective study. / Lee, Jin Ha; Cheon, JaeHee; Jeon, Seong Woo; Ye, Byong Duk; Yang, Suk Kyun; Kim, Young Ho; Lee, Kang Moon; Im, Jong Pil; Kim, Joo Sung; Lee, Chang Kyun; Kim, Hyo Jong; Kim, Eun Young; Kim, Kyeong Ok; Jang, Byung Ik; Kim, Won Ho.

In: Inflammatory Bowel Diseases, Vol. 19, No. 9, 01.08.2013, p. 1833-1838.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of infliximab in intestinal Behçet's disease

T2 - A Korean multicenter retrospective study

AU - Lee, Jin Ha

AU - Cheon, JaeHee

AU - Jeon, Seong Woo

AU - Ye, Byong Duk

AU - Yang, Suk Kyun

AU - Kim, Young Ho

AU - Lee, Kang Moon

AU - Im, Jong Pil

AU - Kim, Joo Sung

AU - Lee, Chang Kyun

AU - Kim, Hyo Jong

AU - Kim, Eun Young

AU - Kim, Kyeong Ok

AU - Jang, Byung Ik

AU - Kim, Won Ho

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment. Methods: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea. We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab. Response rates of infliximab at 2, 4, 30, and 54 weeks for each patient and factors predictive of sustained response were investigated. Adverse events were also identified. Results: The median duration of follow-up after initial infliximab infusion was of 29.5 months. The clinical response rates at 2, 4, 30, and 54 weeks were 75%, 64.3%, 50%, and 39.1%, respectively, with clinical remission rates of 32.1%, 28.6%, 46.2%, and 39.1%, respectively. After multivariate analysis, older age at diagnosis (≥40 yr), female sex, a longer disease duration (≥5 yr), concomitant immunomodulator use, and achievement of remission at week 4 were found to be predictive factors of sustained response. There was 1 serious infection but no malignancies or deaths in this study. Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD. Moreover, we found 5 predictive factors associated with sustained response, which might assist in optimal patient selection for infliximab treatment.

AB - Background: Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its therapeutic efficacy for the treatment of intestinal Behçet's disease (BD) is unknown. We investigated the short-term and long-term response rates to infliximab in intestinal BD and predictive factors of sustained treatment response following infliximab treatment. Methods: This study was conducted using a retrospective noncontrolled review of medical records from 8 tertiary hospitals in Korea. We collected clinical, demographic, and laboratory data for patients with 28 patients with intestinal BD who received at least 1 dose of infliximab. Response rates of infliximab at 2, 4, 30, and 54 weeks for each patient and factors predictive of sustained response were investigated. Adverse events were also identified. Results: The median duration of follow-up after initial infliximab infusion was of 29.5 months. The clinical response rates at 2, 4, 30, and 54 weeks were 75%, 64.3%, 50%, and 39.1%, respectively, with clinical remission rates of 32.1%, 28.6%, 46.2%, and 39.1%, respectively. After multivariate analysis, older age at diagnosis (≥40 yr), female sex, a longer disease duration (≥5 yr), concomitant immunomodulator use, and achievement of remission at week 4 were found to be predictive factors of sustained response. There was 1 serious infection but no malignancies or deaths in this study. Conclusions: Infliximab was a well-tolerated and effective therapy for patients with moderate-to-severe intestinal BD. Moreover, we found 5 predictive factors associated with sustained response, which might assist in optimal patient selection for infliximab treatment.

UR - http://www.scopus.com/inward/record.url?scp=84884636719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884636719&partnerID=8YFLogxK

U2 - 10.1097/MIB.0b013e31828f19c9

DO - 10.1097/MIB.0b013e31828f19c9

M3 - Article

C2 - 23702810

AN - SCOPUS:84884636719

VL - 19

SP - 1833

EP - 1838

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 9

ER -